Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.49 |
| ▸ | GLO1 | Q04760 | 4/20 | 0.43 |
| ▸ | SLC40A1 | Q9NP59 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | LOX | P28300 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL4623813 | 0.98 | L3MBTL1 (0.58) | L3MBTL1KAT6AGLO1SLC40A1NPSR1 | |
| SCHEMBL9430743 | 0.84 | L3MBTL1 (0.49) | L3MBTL1KAT6AGLO1SLC40A1KDM4E | |
| SCHEMBL9434805 | 0.79 | NPSR1 (0.53) | L3MBTL1KAT6AGLO1SLC40A1NPSR1 | |
| SCHEMBL17372076 | 0.77 | L3MBTL1 (0.65) | L3MBTL1KAT6AGLO1SLC40A1KDM4E | |
| SCHEMBL18881310 | 0.77 | L3MBTL1 (0.65) | L3MBTL1KAT6AGLO1SLC40A1KDM4E | |
| SCHEMBL2371864 | 0.74 | L3MBTL1 (0.56) | L3MBTL1KAT6AGLO1SLC40A1KDM4E | |
| SCHEMBL17489126 | 0.74 | L3MBTL1 (0.59) | L3MBTL1KAT6AGLO1SLC40A1KDM4E | |
| SCHEMBL10416944 | 0.74 | KDM4E (0.51) | L3MBTL1KAT6AGLO1SLC40A1KDM4E | |
| SCHEMBL10362240 | 0.73 | L3MBTL1 (0.59) | L3MBTL1KAT6AGLO1SLC40A1KDM4E | |
| SCHEMBL4257915 | 0.73 | L3MBTL1 (0.59) | L3MBTL1KAT6AGLO1SLC40A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101481349-A | Preparation of alkyl pyridine-2-sulfonic acid amide | FUXIN CUSTCHEM FINE CHEMICAL C (CN) | 2009-07-15 | — | — | CN | claimed |
| EP-1200420-B1 | PROCESS FOR MAKING N-ALKYL BIS(THIAZOLYL)SULFENIMIDES | UNIROYAL CHEM CO INC (US) | 2006-01-18 | — | — | EP | claimed |
| EP-1200420-A1 | PROCESS FOR MAKING N-ALKYL BIS(THIAZOLYL)SULFENIMIDES | Uniroyal Chemical Company, Inc. (US) | 2002-05-02 | — | — | EP | claimed |
| WO-2001009108-A1 | PROCESS FOR MAKING N-ALKYL BIS(THIAZOLYL)SULFENIMIDES | UNIROYAL CHEMICAL COMPANY, INC. (US) | 2001-02-08 | — | — | WO | claimed |
| CN-101481349-A | Preparation of alkyl pyridine-2-sulfonic acid amide | FUXIN CUSTCHEM FINE CHEMICAL C (CN) | 2009-07-15 | — | — | CN | disclosed |
| US-7320993-B1 | Aryl-substituted pyridylalkane, alkene, and alkine carboxamides useful as cytostatic useful as cytostatic and immuosuppressive agents | ASTELLAS DEUTSCHLAND GMBH (DE) | 2008-01-22 | — | — | US | disclosed |
| US-7276524-B2 | Pyridyl alkane acid amides as cytostatics and immunosuppressives | ASTELLAS DEUTSCHLAND GMBH (DE) | 2007-10-02 | — | — | US | disclosed |
| US-20070219197-A1 | Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives | ASTELLAS PHARMA GMBH (DE) | 2007-09-20 | — | — | US | disclosed |
| US-7241745-B2 | Pyridyl alkene and pyridyl alkine acid amides as cytostatics and immunosupressives | ASTELLAS PHARMA GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-20070142377-A1 | Pyridyl Alkene and Pyridyl Alkine-Acid Amides as Cytostatics and Immunosuppressives | BIEDERMANN ELFI | 2007-06-21 | — | — | US | disclosed |
| US-7192967-B1 | Cyclic imide-substituted pyridylalkane, alkene, alkine carboxamides useful as cytostatic and immunosuppressive agents | ASTELLAS PHARMA GMBH (DE) | 2007-03-20 | — | — | US | disclosed |
| EP-1044197-B1 | PIPERIDINYL-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKYNE CARBOXAMIDES AS CYTOSTATIC AGENTS AND IMMUNOSUPPRESSANTS | ASTELLAS PHARMA GMBH (DE) | 2006-04-19 | — | — | EP | disclosed |
| EP-0923570-B1 | PYRIDYL ALKENE- AND PYRIDYL ALKINE- ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES | FUJISAWA DEUTSCHLAND GMBH (DE) | 2002-09-25 | — | — | EP | disclosed |
| EP-0912176-B1 | USE OF PYRIDYL ALKANE, PYRIDYL ALKENE AND/OR PYRIDYL ALKINE ACID AMIDES IN THE TREATMENT OF TUMORS OR FOR IMMUNOSUPPRESSION | FUJISAWA DEUTSCHLAND GMBH (DE) | 2002-09-25 | — | — | EP | disclosed |
| US-6451816-B1 | Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression | KLINGE PHARMA GMBH (DE) | 2002-09-17 | — | — | US | disclosed |
| EP-0934309-B1 | NEW PYRIDYL ALKANE ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES | FUJISAWA DEUTSCHLAND GMBH (DE) | 2002-09-11 | — | — | EP | disclosed |
| US-6444823-B1 | ANTITUMOR AGENTS; IMMUNOSUPPRESSANTS; SIDE EFFECT REDUCTION | KLINGE PHARMA GMBH (DE) | 2002-09-03 | — | — | US | disclosed |
| EP-0934309-A1 | NEW PYRIDYL ALKANE ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES | Klinge Pharma GmbH (DE) | 1999-08-11 | — | — | EP | disclosed |
| EP-0912176-A1 | USE OF PYRIDYL ALKANE, PYRIDYL ALKENE AND/OR PYRIDYL ALKINE ACID AMIDES IN THE TREATMENT OF TUMORS OR FOR IMMUNOSUPPRESSION | Klinge Pharma GmbH (DE) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997048695-A1 | NEW PYRIDYL ALKANE ACID AMIDES AS CYTOSTATICS AND IMMUNOSUPPRESSIVES | KLINGE PHARMA GMBH (DE) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219197-A1 | Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives | NFATC1, PDCD1, ACIN1 | L3MBTL1 2297/4885KAT6A 4670/4885GLO1 1467/4885 |
| US-20070142377-A1 | Pyridyl Alkene and Pyridyl Alkine-Acid Amides as Cytostatics and Immunosuppressives | ALK, TYMP, PDCD1 | L3MBTL1 3185/4885KAT6A 4410/4885GLO1 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.